Dynamics and pathways of assembly in membrane pore formation

Lead Research Organisation: Birkbeck, University of London
Department Name: Biological Sciences

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

We will use real-time atomic force microscopy (AFM), single particle electron microscopy (EM) and electron tomography to track the dynamics and the pathways of assembly of pore-forming proteins on and in membranes. We will focus on the superfamily of cholesterol dependent cytolysins (CDCs) and membrane attack complex/perforin (MACPF) pore-forming proteins. Though atomic structures of CDC and MACPF proteins have been determined for the soluble monomers, along with low resolution maps of the membrane-inserted pores, the dynamics and pathways of assembly are much harder to address experimentally. To find assembly pathways, we will trap intermediate assemblies with disulphide locked variants and reduced temperatures, and determine their structures by EM. Moreover, benefitting from recent developments on fast-scanning AFM, we will follow the assembly and pore formation by real-time imaging of the functional proteins on planar-supported model membranes. Combining the two methods, we will determine the sequential steps in the assembly of the prepore and pore state of bacterial CDCs and of the MACPF protein perforin. By probing inside the rings with AFM, we will also investigate the fate of the lipid bilayer in the pores upon assembly of bacterial CDCs. We will elucidate biophysical mechanisms that are fundamental to pathogen attack and immune defence. This information is anticipated to create opportunities for new drug design, either by stabilising pore-forming proteins to prevent pore formation, or in stabilising or enhancing their membrane-bound forms, in case of deficient pore-forming activity.

Planned Impact

This proposal aims at elucidating the biological and biophysical mechanisms of membrane pore formation by bacterial toxins and immune mediators. The superfamily of membrane attack complex/perforin (MACPF) and cholesterol-dependent cytolysin (CDC) proteins that it focuses on are of significant medical importance. The CDC perfringolysin O rapidly induces irreversible cellular injury in a deadly form of gangrene that is caused by the bacterium Clostridium perfringens. The CDC pneumolysin is a major virulence factor of Streptococcus pneumoniae, at the root of bacterial pneumonia, still a major cause of death and illness throughout the world despite the widespread use of antibiotics. When released in the lungs, pneumolysin damages the lung tissue and its blood vessels. Antibiotics may exacerbate lung damage because they are designed to kill the bacteria by breaking them open, which leads to the further release of pneumolysin. Perforin is the main weapon of natural killer cells. It punches holes in virally infected or cancerous cells that have been detected by the immune system, and delivers lethal granzymes through these holes. Babies born with defective perforin succumb to viral infections or tumours early in life. On the other hand, if perforin is too active, normal cells can be incorrectly killed.

By elucidating the mechanism of membrane pore formation by pore-forming proteins, we will create new opportunities for drug design: e.g., the prevention of pore formation by pneumolysin would be a significant advance in the treatment of bacterial pneumonia; the ability to control the activity of MACPF proteins in the human immune system could be an important means of regulating the immune response during and after tissue and organ transplantation or could alleviate the perforin-dependent cytotoxicity in autoimmune diabetes.

In addition, the proposed methodology for studying membrane pore formation is not restricted to pore-forming proteins alone. It can be applied to a variety of other medically relevant interactions between membranes and macromolecules. Examples of this are antimicrobial peptides that are currently investigated as new therapies against bacterial infections, as well as pH-sensitive polymers that are used for intracellular drug (e.g., gene and RNA therapies) delivery across the barrier formed by endosomal membranes after cellular drug in-take via endocytosis. We anticipate that the development of such novel therapeutic approaches will be enhanced by molecular-scale understanding as can be achieved with the methods outlined in this proposal.

On the shorter term (several years), this research will thus benefit pharmaceutical industry and biomedical SMEs. On the longer term (10-20 years, given the lead times for drug development), it will have an impact on healthcare practitioners and patients.

Further impact can be achieved on the AFM technology. With this project, we propose a new application of fast-scanning AFM techniques that have only recently been developed. For such a young technology, feedback based on relevant applications is crucial. It helps to adjust the technology such that it can make a larger impact over a wider range of applications, which will benefit nanotechnological SMEs.

Given the power of high-quality images and movies such as can be produced by in particular AFM, we also anticipate an educational impact to the lay audience by demonstrating a powerful and biomedically relevant application of basic sciences and nanotechnology.

Publications

10 25 50
 
Description We have developed real time atomic force microscopy imaging of membrane pore formation and correlated findings with electron microscopy of the same samples, to give us a new understanding of the action of proteins used by both bacterial pathogens and our immune system to punch holes through membranes. Their actions are key parts of either pathogen attack or immune defence.
Exploitation Route These methods can be used to study other macromolecular machines, and can be used in biotechnology and pharmaceutical industries, eg in drug or vaccine development.
Sectors Healthcare,Pharmaceuticals and Medical Biotechnology